Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumour heterogeneity and the evolution of polyclonal drug resistance.

Molecular oncology - 12 Sept 2014

Burrell Rebecca A, Swanton Charles

Abstract excerpt

Cancer drug resistance is a major problem, with the majority of patients with metastatic disease ultimately developing multidrug resistance and succumbing to their disease. Our understanding of molecular events underpinning treatment failure has been enhanced by new genomic technologies and pre-clinical studies. Intratumour genetic heterogeneity (ITH) is a prominent contributor to therapeutic failure, and it is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cancer Genomics and Diagnostics
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Heterogeneity

Share to Genomic Instability

Share to Lung Cancer Treatments and Mutations

Share to Mutation

Share to Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 25087573
DOI: 10.1016/j.molonc.2014.06.005
PMCID: PMC5528620

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumour heterogeneity and the evolution of polyclonal drug resistance.PMID 25087573Read ↗

Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives.Semantic proximity Read ↗

Drug Resistance in Cancers: A Free Pass for BullyingSemantic proximity Read ↗

Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution.Semantic proximity Read ↗

Drug resistance: origins, evolution and characterization of genomic clones and the tumor ecosystem to optimize precise individualized therapySemantic proximity Read ↗

Role of Intratumoral Heterogeneity in Metastatic Progression and Drug ResistanceSemantic proximity Read ↗

The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcomeSemantic proximity Read ↗

Clonal morphology-guided combination therapies overcome heterogeneity-driven drug toleranceSemantic proximity Read ↗

Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future.Semantic proximity Read ↗

Tumour heterogeneity and resistance to cancer therapiesSemantic proximity Read ↗

Mechanisms and insights into drug resistance in cancerSemantic proximity Read ↗

Tumour heterogeneity and immune-modulationSemantic proximity Read ↗

Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.